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Abstract.
Background: The APOE ε4 allele is the strongest known genetic risk factor for sporadic Alzheimer’s disease (AD). The
neighboring TOMM40 gene has also been implicated in AD due to its close proximity to APOE.
Objective: Here we tested whether methylation of the TOMM40-APOE locus may influence ApoE protein levels and AD
pathology.
Methods: DNA methylation levels across the TOMM40-APOE locus and ApoE levels were measured in superior frontal
gyrus tissues of 62 human brains genotyped for APOE and scored for AD neuropathology.
Results: Methylation levels within the TOMM40 CpG island in the promoter or APOE CpG island in Exon 4 did not differ
between APOE ε4 carriers versus non-carriers. However, APOE ε4 carriers had significantly higher methylation the APOE
promoter compared with non-carriers. Although DNA methylation at TOMM40, APOE promoter region, or APOE did not
differ between AD pathological groups, there was a negative association between TOMM40 methylation and CERAD scores.
ApoE protein concentrations did not significantly different between APOE ε4 carriers and non-carriers, or between AD
pathological groups. Finally, there was no correlation between ApoE protein concentrations and DNA methylation levels.
Conclusion: APOE gene methylation may not be affected by genotype, relate to AD pathology or ApoE protein levels in
the superior frontal gyrus, though, DNA methylation at the ApoE promoter differed between genotype. DNA methylation at
TOMM40 associated with amyloid- plaques and longitudinal fluid intelligence. In sum, these results suggest a complicated
regulation of the TOMM40-APOE locus in the brain in controlling ApoE protein levels and AD neuropathology.
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INTRODUCTION
Apolipoprotein E, encoded by the APOE gene,
is an important lipid transport protein in the cen-
tral nervous system. There are three major isoforms
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(ε2, ε3, and ε4) in humans. The presence of the ε4
allele is the strongest known genetic risk factor for
late-onset Alzheimer’s disease (AD); carrying one ε4
allele increases the risk of AD by 2- to 3-fold, while
the presence of two ε4 alleles increases the risk by
approximately 12-fold compared to individuals with-
out any ε4 alleles. Carriers of APOE ε2 allele, on
the other hand, are protected against AD [1]. How-
ever, not all ε4 carriers develop AD and therefore it
may be possible that other ε4-allele-associated inter-
acting factors, such as epigenetic mechanisms, could
contribute towards the complex disease etiology [2].
Exon 4 of APOE contains a CpG island, and
interestingly the two C/T single nucleotide polymor-
phisms (SNPs; rs429358 and rs7412) that determine
the different ε2, ε3, and ε4 alleles, both of which can
alter CpG dinucleotides. The ε4 allele introduces two
additional CpG dinucleotides in the CpG island at
rs429358 and rs7412, while ε3 introduces a CpG at
rs7412 only and the ε2 allele lacks both the two CpG
sites present in the ε4 allele [3]. It is hypothesized
that such allelic differences in the CpG island could
lead to allele-specific epigenetic changes that may
contribute toward AD risk.
TOMM40, coding for the gene translocase of outer
mitochondrial membrane 40, is in strong linkage
disequilibrium with APOE. Genome-wide studies
have identified variants within TOMM40 that asso-
ciate with risk of AD [4, 5], while a further study
showed blood TOMM40 expression was downregu-
lated in subjects with AD compared with controls and
the expression also correlated with cognitive decline
[6]. The superior frontal gyrus, known to be heavily
involved in a variety of cognitive tasks [7], is among
the regions that show the greatest age-related surface
area reductions [8], which further predicts risk of cog-
nitive decline and dementia [9]. Furthermore, it has
been shown that relative to ε3/3 genotypes, brains
of ε3/4 genotypes show a significantly thinner cortex
within the superior frontal gyrus [10].
Here we investigate whether the TOMM40-APOE
locus is differentially methylated in AD brains and
controls. We hypothesized that TOMM40 methyla-
tion is increased in AD brains and correlated with
cognitive decline. We further considered if APOE
methylation is also increased in AD brains, lead-
ing to reduced levels of ApoE protein by regulating
ApoE protein expression, and that the methylation
levels might associate with AD pathology. Finally,
we tested whether the APOE alleles affect DNA




Fresh, frozen tissue was taken from the supe-
rior frontal gyrus (Brodmann area 8). Samples were
acquired from donors through the Manchester Brain
Bank. Ethical approval was granted from the Man-
chester Brain Bank Committee. Donors were partic-
ipants of a large prospective cognitive ageing cohort
known as The University of Manchester Age and
Cognitive Performance Research Cohort [11, 12] and
included all those with available brain tissue and
neuropathological data. The participants included 46
females and 21 males of Caucasian population from
Manchester and Newcastle. The study took place
over four waves between 1985 and 2002. Cogni-
tive phenotypes (g factors) for vocabulary ability,
memory, processing speed, and fluid intelligence for
both cross-sectional (baseline scores) and longitu-
dinal (baseline and subsequent scores) data were
generated using Stata (StataCorp., College Station,
TX: StataCorp LP). Empirical Bayes’ estimates for
each individual were obtained from a random effects
model fitted by maximum likelihood to the standard-
ized age-regressed residuals obtained for each sex
from the cognitive test scores. All g factors were
corrected for age and the longitudinal data corrected
for practice effects. Standardized residuals were used
for analyses. For longitudinal g factors, missing data
points were imputed by sampling the posterior distri-
bution of factor scores using Mplus. The vocabulary
ability (crystallized intelligence) factor was gener-
ated using tests that comprised the Mill Hill and Wais
vocabulary tests [13, 14]. Cognitive tests used for
fluid factors were the two parts of the Alice Heim
test 4 [15] and the four subtests of the Culture Fair
Test [16]. Speed factors were derived from the Alpha-
bet Coding Task and the Random Letters test [17].
Factors for memory were generated from immediate
and delayed recall, propositions, and spatial memory
tests. These tests ceased in 2004 due to the increas-
ing frailty of the volunteers (mean age, 78.9 years;
2004–2006 n = 729). The method of the cognitive
assessment was previously described [11].
Thal phase [18], Braak stage [19], and CERAD
score [20] were investigated as well as stratifica-
tion into groups (None, Low, Intermediate, and High)
based on the ‘ABC score’ recommended by National
Institute on Aging–Alzheimer’s Association [21],
which incorporates histopathological assessments for
amyloid- deposits (A), staging of neurofibrillary
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Fig. 1. Schematic representation of TOMM40-APOE locus showing approximate locations of the regions investigated in this study. Black
bars represent CpG islands. Grey bars represent gene exons. Transcription of the genes occurs from left to right as shown by arrows.
Table 1
Cohort characteristics stratified by AD pathological change group
AD pathological change group
Variable Not (n = 16) Low (n = 19) Intermediate (n = 25) High (n = 6) p (test statistic)
Age at death, y (SD) 86.5 (6.4) 87.6 (5.1) 87.7 (6.3) 88.5 (8.5) 0.895 (F = 0.202)
Females, n (%) 9 (56) 15 (79) 17 (68) 5 (83) 0.440 (χ2 = 2.702)
Postmortem delay, h (SD)a 76.6 (56.6) 72.1 (44.0) 79.8 (38.9) 67.2 (29.2) 0.922 (F = 0.161)
Whole brain weight, g (SD)b 1217 (156.6) 1167 (118.7) 1227 (149.2) 1312 (31.8) 0.445 (F = 0.910)
APOE ε4 carrier, n (%) 1 (6) 6 (32) 12 (48) 3 (50) 0.037 (χ2 = 8.478)
aData available in: Not n = 14, Low n = 19, Intermediate n = 21, High n = 5 bData available in: Not n = 8, Low n = 14, Intermediate n = 18,
High n = 2.
tangles (B), and scoring of neuritic plaques (C) to
define 4 stages: Not, Low, Intermediate and High.
Raw scores between two values were rounded up.
DNA methylation analysis
The TOMM40 promoter, APOE exon 4, and APOE
promoter region were identified using previous pub-
lications [3, 22, 23] and the University of California
Santa Cruz genome browser. Figure 1 shows the
approximate location of the investigated CpGs in the
TOMM40-APOE locus.
Genomic DNA was extracted using the Isolate
II Genomic DNA kit (Bioline, London, UK) and
500 ng bisulfite-converted using the EpiMark Bisul-
fite Conversion Kit (New England Biolabs, Hitchen,
UK) as previously described [24]. Primers used
for DNA amplification and pyrosequencing were
designed using Pyromark Assay Design SW 2.0
(Qiagen, Hilden, Germany) and manufactured by In
vitro gen (Thermo Fisher Scientific, Cambridge, UK).
PCRs were performed using 2 l of the bisulphite
converted template DNA in MyTaq HS mix PCR
reagents (Bioline, London, UK) including 0.2 M
each of the forward and reverse (biotinylated) primers
with the following conditions for all primer sets: ini-
tial denaturation of 5 min 95◦C; 49 cycles of 95◦C
for 30 s, 58◦C for 30 s, 72◦C for 30 s; final extension
of 72◦C for 5 min. For the TOMM40 (CpG island and
promoter) we assessed 2 CpG sites using a forward
and biotinylated reverse primer, for the APOE pro-
moter region 2 CpG sites were also assesses while
11 CpG sites were assessed across the APOE exon
4 regions (see Table 1 for all primer sequences).
Following PCR, single-stranded biotinylated prod-
uct was purified by mixing 10 l of the amplification
mixture, 2 l of streptavidin sepharose HP (Amer-
sham Biosciences, UK), and 40 l of binding buffer.
The sepharose beads containing the immobilized
biotinylated product were purified, washed, and dena-
tured in 0.2 mol/l NaOH and washed again using
the Pyrosequencing Vacuum Prep Tool (Qiagen).
The biotinylated DNA was resuspended in 12 l of
annealing buffer containing 0.3 mol/l pyrosequenc-
ing primer (see Table 1 for all pyrosequencing primer
sequences). Two sequencing primers covering neigh-
boring regions of the APOE exon 4 region were used
and the sequence to analyze altered to allow for the
polymorphic sites in the different genotypes. DNA
methylation of CpG residues within the different
278 N. Bezuch et al. / Epigenetic Regulation of TOMM40-APOE in AD
Table 2
Sequences in TOMM40 promoter CpG island APOE promoter region and APOE exon 4 CpG island analyzed in this study and primers used
for their amplification and sequencing
Gene location Primers; Forward, reverse, sequencing ∗ Biotin tagged Sequence analyzed (CpGs numbered) 5′-3′
























regions were quantified by pyrosequencing using the
PyroMark Q24 Advanced system with the PyroGold
SQA reagent kit (Qiagen, Manchester, UK). The per-
centage methylation for each of the CpG sites was
calculated using Pyro Q-CpG software (Qiagen). All
assays performed in duplicate and final values repre-
sent an average of this.
ApoE protein quantification
The lysate used for the ApoE protein quantifica-
tion was extracted from the brain tissue using RIPA
buffer (Sigma, UK) and 1x protease inhibitor cock-
tail (Sigma, UK), as described previously [25]. The
concentration of ApoE protein in tissue samples were
measured using the Apolipoprotein E Human ELISA
kit (Abcam, Cambridge, UK) according to the man-
ufacturer’s instructions and as previously described
in brain lysates [26]. Absorbances at 450 and 570 nm
were measured using Synergy HT microplate reader
(BioTek Instruments, Inc., VT, US) and a 7-point
standard curve generated in GraphPad. Sample ApoE
concentrations were then interpolated and concen-
trations were standardized to account for the total
protein input.
Genotyping
Genotyping of the APOE rs7412 and rs429358
polymorphisms to enable APOE allele status was
previously performed using the Sequenom Mas-
sARRAY iPLEX platform [27]. APOE alleles were
defined as: ε2 = T (rs429358)/T (rs7412); ε3 = T
(rs429358) / C (rs7412); ε4 = C (rs429358) / C
(rs7412).
Statistical analysis
All statistical analyses were performed in Graph-
Pad Prism (version 9). To assess differences between
continuous patient characteristic variables between
groups, we used either a one-way ANOVA or
unpaired t-test. For categorical patient characteristic
variables, differences between groups were assessed
with either a Pearson chi-squared or Fisher’s exact
test. DNA methylation of individual CpG sites with
each region of interest were averaged using the
geometric mean and log2-transformed prior to sta-
tistical testing. ApoE protein concentrations were
square-root transformed prior to statistical testing.
Group differences were assessed using either a one-
way ANOVA or unpaired t-test. Spearman rank
correlation was used to assess correlations between
variables. Linear regression, using SPSS version 24,
was used to levels of TOMM40 methylation with lon-
gitudinal and cross-sectional measures of cognition.
RESULTS
Cohort characteristics
Clinical and pathological characteristics of the
study sample stratified by AD pathological groups
can be found in Table 1. All groups were well matched
for donor age at death, sex, postmortem delay time,
and whole brain weight. Cohort characteristics strat-
ified by APOE ε4 status can be found Supplementary
Table 1. The frequency of APOE ε4 carriers increased
with more severe AD pathological changes.
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Fig. 2. TOMM40 CpG island (A), APOE promoter (B), and APOE CpG island (C) methylation differences between groups. Horizontal lines
represent mean group values. TOMM40 n = 67; APOE promoter n = 66, APOE CpG island n = 64.
TOMM40-APOE locus DNA methylation
Levels of DNA methylation at the TOMM40
CpG island (F = 0.386, p = 0.764), APOE promoter
region (F = 0.806, p = 0.495), and APOE CpG island
(F = 0.306, p = 0.821) did not significantly differ be-
tween AD pathology groups (Fig. 2) or between
gender (all p > 0.05). TOMM40 methylation was
negatively association with CERAD severity scores
(rho = –0.254, p = 0.045; Supplementary Figure 1)
though, this is a nominal p-value and not corrected
multiple testing. When testing TOMM40 methyla-
tion with cognitive measures, regression analy-
ses revealed significant negative correlations with
both cross-sectional fluid intelligence (B = –0.655,
p < 0.001) and longitudinal fluid intelligence (B =
–0.368, p = 0.013), but not with vocabulary (cross-
sectional, B = –0.493, p = 0.24; longitudinal, B =
0.537, p = 0.201) or memory (cross-sectional, B =
0.134, p = 0.469; longitudinal, B = –0.082, p = 0.658).
APOE DNA methylation, protein concentrations
and APOE ε4 carrier status
Next, we grouped samples according to APOE ε4
status. There was no difference in methylation lev-
els for the TOMM40 (t = 0.755, p = 0.456) or APOE
(t = 0.334, p = 0.742) regions between APOE ε4 carri-
ers (homozygous/heterozygous ε4) and non-carriers.
However, APOE ε4 carriers had significantly higher
methylation levels at the APOE promoter region,
compared with non-carriers (t = 2.158, p = 0.035;
Fig. 3).
ApoE protein levels did not significantly dif-
ferent between APOE ε4 carriers and non-carriers
(t = 1.624, p = 0.110), or between AD pathological
groups (F = 1.069, p = 0.370). Further, when analyz-
ing all samples collectively, there was no correlation
between ApoE protein levels and DNA methylation
Fig. 3. Estimation plot for APOE promoter region methylation
differences between APOE ε4 carriers and non-carriers. Hori-
zontal lines represent mean group values. Difference between
group means with 95% confidence intervals is also plotted. n = 66.
∗p < 0.05.
levels (rho = –0.041, p = 0.793; Supplementary Fig-
ure 1).
DISCUSSION
The results of this study show that APOE ε4 allele
status did not affect APOE methylation but was asso-
ciated with a difference in methylation levels within
the APOE promoter region. Though DNA methyla-
tion at TOMM40 or APOE did not differ between
AD pathological groups, TOMM40 methylation was
associated with lower CERAD scores and reduced
measures of cross-sectional and longitudinal fluid
intelligence. ApoE protein concentrations did not
significantly differ with APOE ε4 allele status or
between AD pathological groups, and there were
no correlations between ApoE protein concentrations
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and DNA methylation levels at the APOE promoter
region or Exon 4 CpG island.
It was hypothesized that the APOE exon 4 region
methylation level may differ between the genotypes,
especially as the rs7412 (C/T) removes a CpG site,
and the rs429358 (T/C) creates an extra CpG site.
This study, however, did not find any significant dif-
ference between the methylation levels of the APOE
exon 4 CpG island. One previous study, has shown
higher APOE exon 4 CpG island methylation in the
frontal lobe among carriers of ε3/ε4 genotypes com-
pared to the ε3/ε3 carriers [3]. However, the effect
was only seen in the controls but not in AD cases
and the sample size was small (n = 25). Other studies
that investigated the APOE locus methylation did not
observe any genotype effect on the methylation lev-
els [23], and they did not investigate the difference in
methylation between different genotypes [2, 22].
Interestingly, there were lower levels of methy-
lation in the promoter region of APOE ε4 carriers.
Two studies investigating blood DNA, reported dif-
ferential methylation at CpGs in the APOE promoter
(cg04406254, cg01032398) with AD and cognition,
suggesting a possible regulatory role [23]. Both these
CpGs were in close proximity to the CpGs we found
associated in this study. A twin study found that
methylation in the promoter, but not the exon 4
CpG island, increased the risk of AD; however, they
found no association with APOE ε4 and methylation
and stratification on genotype suggesting the asso-
ciation between promoter methylation and AD was
not genotype-specific. Another study found methy-
lation at the promoter was significantly negatively
correlated with cognitive function in a study of 289
African Americans with a mean age of 67 [28].
DNA methylation at TOMM40 or APOE did not
differ between AD neuropathological groups when
stratified using the ABC score. However, DNA
methylation at the TOMM40 promoter negatively
associated with CERAD scores supporting that its
regulation might relate to amyloid- plaque amy-
loid deposition [29]. That APOE methylation did not
differ with AD neuropathology appears contrary to
some previously published studies showing differ-
ential methylation of APOE Exon 4 CpG island in
AD brains compared with controls, in an APOE-
genotype-specific manner [3], and lower methylation
in frontal lobe, but not cerebellar, tissue from AD
brains compared with controls, suggesting tissue-
specific dysregulations [2]. Shao et al. [22] found
CpG methylation across the locus significantly dif-
fered between AD and cognitively normal controls
in a small number of 12 cerebellum and hippocampal
samples, while methylation did not different between
AD and cognitively normal controls in 67 blood sam-
ples. Perhaps, the results in the superior frontal gyrus
might suggest a different mechanism.
TOMM40 polymorphisms have been reported
to increase susceptibility to AD [30]. TOMM40
rs10524523 variable poly-T repeats were found to be
associated with AD risk and age at onset [31], while
rs157581-G conferred an increased risk for devel-
oping AD and mild cognitive impairment (MCI) in
patients [32]. In the previously mentioned study by
Liu et al., a further CpG site in TOMM40 was found
to show a significant inverse association between
methylation level and delayed recall [28]. A fur-
ther study on the University of Manchester Age and
Cognitive Performance Research Cohort found that
poly-T repeat polymorphism, which associates with
reduced gene expression, associated with reduced
cognition in the same cases studied here [33]. It is
therefore interesting that the present study suggests
that methylation at the TOMM40 promoter negatively
associated with a measure of cognition.
Here we found that ApoE protein levels in the
brains did not differ with APOE ε4 allele status,
between AD pathological groups, or correlate with
DNA methylation levels at the APOE promoter region
or Exon 4 CpG island suggesting that APOE geno-
types may modulate AD risk independently of total
ApoE protein production. That ApoE protein levels
did not differ between APOE ε4 carriers and non car-
riers would suggest that APOE genotype does not
affect protein expression in the superior frontal gyrus.
These findings differ from some previous publica-
tions in which APOE ε4 allele has been associated
with decreased ApoE protein levels in in vitro studies
[34], mouse brains and human frontotemporal lobe
[35]. However, the absolute levels of the ApoE ε3
protein were similar between carriers of ε3/ε3 and
ε3/ε4 genotype, suggesting that the overall decrease
in the ApoE protein levels could be due to the reduc-
tion in the ε4 isoform. Here we only measured the
total ApoE levels and not the levels of the specific
APOE isoforms. This could mean that the overall
ApoE levels do not significantly affect AD pathol-
ogy development and the effect is isoform-specific,
though the few findings from studies on this are incon-
sistent [36]. According to Riddell et al., APOE ε4
has a shorter half-life and is degraded at a higher
rate than APOE ε3, which might be the cause for an
overall decreased ApoE protein levels in the APOE
ε4 carriers [34]. An isoform-specific ApoE protein
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quantification would allow us to assess the effect of
the individual genotypes more accurately.
There are several limitations to this study. With
multifactorial diseases such as dementia and AD,
individual SNPs or gene-specific methylation, may
confer only a modest influence on the pathology and
the diseases risk, and thus may require larger sam-
ple sizes to provide the necessary statistical power to
detect small effects. As a result of a large postmortem
delay in some samples, the levels of mRNA were of
poor quality with low RIN values. Therefore, we were
unable to measure ApoE and TOMM40 mRNA levels
which may provide an insight into how APOE methy-
lation directly affects the level of mRNA transcripts
and which CpG sites may have a significant effect.
Another limitation are the unknown potential effects
that the AD pathological changes could have on cell
fractions, for example reduced neurons and increased
glial cells and how these changes may influence the
results. Finally, we should also consider the possi-
ble role of sex-differences. Though methylation did
not differ between genders, this study was not large
enough to test for sex-differences in gene-specific
regulation in AD neuropathology.
Sporadic AD is a complex disorder, displaying
heterogeneous pathogenesis, and numerous genetic
variants together with environmental factors may
interact to influence the diseases risk. TOMM40-
APOE locus methylation might influence the risk of
AD by modulating ApoE protein expression directly
in the brain. This is the first study to investigate APOE
methylation with protein levels in the brain suggest-
ing there is no association, or we lack the power
to detect it. The association between APOE geno-
type/APOE promoter methylation and the TOMM40
promoter methylation, suggests possible regulatory
mechanisms that may or may not interact. More work
is needed to understand these molecular mechanisms
within the brain and AD neuropathology.
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